To: Lazarus Long who wrote (40873 ) 3/19/1999 4:36:00 PM From: MARK C. Read Replies (2) | Respond to of 50264
Like Bill Gates really needs more money. Wont be able to call him Mr. Softy anymore. <g> Microsoft challenge to Viagra sex pill by Toby Rose and Geraint Smith This is London 19 March, 1999 An offshoot of Microsoft is threatening to overshadow its parent's reputation for software after developing a "super rival" to Viagra. The effects of the new anti-impotency drug, as yet unnamed, are said to be immediate, to last 24 hours, and to result in a male response to sexual stimuli that would shame the most rampant adolescent. "Older people who have tried the drug say that they have the erections of a 15-year-old," Professor Albert Leriche, a Lyon urologist, told a medical symposium in Paris today. Tests on human volunteers have so far been "very encouraging," he said, and have shown that the new drug has several advantages over the trailblazing Viagra. "The effects of the drug can appear at any time during the 24 hour period although, as with Viagra, stimulation is required. "For example it is possible that men will become excited just by seeing a pretty girl on the beach or in the street. "With this drug the user is always ready." Professor Leriche is conducting tests and says he is very excited by the results. The American laboratory ICOS says it will be on the market within two years. If it does get through the process of clinical trials necessary before it is licensed, it might bring Bill Gates yet more superfluous wealth. When Viagra first came on to the market, shares in Pfizer, its maker, shot skywards, and the company has been extremely quick to defend what is now probably its hottest trade name. The new drug will have to go through extensive tests before it is licensed - especially given the initial concerns about the effects on health of Viagra. As many as 24 deaths from heart attacks have been blamed on that drug. © Associated Newspapers Ltd., 19 March 1999thisislondon.co.uk . Next Previous | Previous | Next | Respond | Quotes - 100-Day Chart - News - Profile - Earnings - Discussion - Biotechnology